JP2023533519A5 - - Google Patents
Info
- Publication number
- JP2023533519A5 JP2023533519A5 JP2023500332A JP2023500332A JP2023533519A5 JP 2023533519 A5 JP2023533519 A5 JP 2023533519A5 JP 2023500332 A JP2023500332 A JP 2023500332A JP 2023500332 A JP2023500332 A JP 2023500332A JP 2023533519 A5 JP2023533519 A5 JP 2023533519A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- halo
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050220P | 2020-07-10 | 2020-07-10 | |
| US63/050,220 | 2020-07-10 | ||
| PCT/US2021/040420 WO2022010828A1 (en) | 2020-07-10 | 2021-07-06 | Plasma kallikrein inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533519A JP2023533519A (ja) | 2023-08-03 |
| JP2023533519A5 true JP2023533519A5 (enExample) | 2024-06-03 |
| JP7773522B2 JP7773522B2 (ja) | 2025-11-19 |
Family
ID=79552050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500332A Active JP7773522B2 (ja) | 2020-07-10 | 2021-07-06 | 血漿カリクレイン阻害薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12528786B2 (enExample) |
| EP (1) | EP4178620B1 (enExample) |
| JP (1) | JP7773522B2 (enExample) |
| KR (1) | KR20230038526A (enExample) |
| CN (1) | CN116157154B (enExample) |
| AU (1) | AU2021306250A1 (enExample) |
| CA (1) | CA3185597A1 (enExample) |
| MX (1) | MX2023000507A (enExample) |
| WO (1) | WO2022010828A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4210694B1 (en) * | 2020-09-10 | 2025-10-15 | Merck Sharp & Dohme LLC | Plasma kallikrein inhibitors |
| WO2024173196A1 (en) * | 2023-02-17 | 2024-08-22 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| WO2026096331A1 (en) * | 2024-10-30 | 2026-05-07 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8609866B2 (en) | 2009-12-18 | 2013-12-17 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
| HRP20221373T1 (hr) | 2014-03-07 | 2023-01-06 | Biocryst Pharmaceuticals, Inc. | Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi |
| KR102286305B1 (ko) | 2014-07-16 | 2021-08-09 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| WO2017001926A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc | Therapeutic inhibitory compounds |
| WO2017072020A1 (en) * | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| US10640486B2 (en) * | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| BR112018008506B8 (pt) | 2015-10-29 | 2023-12-05 | Merck Sharp & Dohme | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos |
| EP3612523B1 (en) | 2017-04-21 | 2021-06-09 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| CN113039181B (zh) * | 2018-08-16 | 2024-08-13 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 |
| KR102931248B1 (ko) * | 2020-06-16 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
-
2021
- 2021-07-06 EP EP21837278.7A patent/EP4178620B1/en active Active
- 2021-07-06 US US18/014,787 patent/US12528786B2/en active Active
- 2021-07-06 CN CN202180055135.6A patent/CN116157154B/zh active Active
- 2021-07-06 AU AU2021306250A patent/AU2021306250A1/en active Pending
- 2021-07-06 CA CA3185597A patent/CA3185597A1/en active Pending
- 2021-07-06 KR KR1020237004707A patent/KR20230038526A/ko not_active Withdrawn
- 2021-07-06 MX MX2023000507A patent/MX2023000507A/es unknown
- 2021-07-06 WO PCT/US2021/040420 patent/WO2022010828A1/en not_active Ceased
- 2021-07-06 JP JP2023500332A patent/JP7773522B2/ja active Active